Advertisement
Screener

GENELUX CORPORATION (GNLX) Investment Income, Interest

1.7 / 5 stars · 8/23 Roast Me

GENELUX CORPORATION Investment Income, Interest

GENELUX CORPORATION (GNLX) reported Investment Income, Interest of $127.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Income Statement › Other Income

us-gaap:InvestmentIncomeInterest · last filed 2026-08-13

  • GENELUX CORPORATION investment income, interest for the quarter ending 2026-06-30 was $127.00K, a 43.30% decline year-over-year.
  • GENELUX CORPORATION investment income, interest for the quarter ending 2026-03-31 was $173.00K, a 5.98% decline year-over-year.
  • GENELUX CORPORATION investment income, interest for the quarter ending 2025-12-31 was $128.00K, a 36.32% decline year-over-year.
  • GENELUX CORPORATION investment income, interest for the quarter ending 2025-09-30 was $175.00K, a 21.17% decline year-over-year.
  • GENELUX CORPORATION investment income, interest for fiscal 2025 was $711.00K, a 1.57% increase from fiscal 2024.
  • GENELUX CORPORATION investment income, interest for fiscal 2024 was $700.00K, a 284.62% increase from fiscal 2023.
  • GENELUX CORPORATION investment income, interest for fiscal 2023 was $182.00K.
Period endInvestment Income, Interest 3 monthInvestment Income, Interest 3 month as first filedInvestment Income, Interest 6 monthInvestment Income, Interest 6 month as first filedInvestment Income, Interest 9 monthInvestment Income, Interest 9 month as first filedInvestment Income, Interest 12 monthInvestment Income, Interest 12 month as first filed
2026-06-30$127.00K
10-Q · filed 2026-08-13
$300.00K
10-Q · filed 2026-08-13
$428.00K
derived: sum of 3 quarters · filed 2026-08-13
$603.00K
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$173.00K
10-Q · filed 2026-05-07
$301.00K
derived: sum of 2 quarters · filed 2026-05-07
$476.00K
derived: sum of 3 quarters · filed 2026-05-07
$700.00K
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$128.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
$303.00K
derived: sum of 2 quarters · filed 2026-03-19
$527.00K
derived: sum of 3 quarters · filed 2026-08-13
$711.00K
10-K · filed 2026-03-19
2025-09-30$175.00K
10-Q · filed 2025-11-05
$399.00K
derived: sum of 2 quarters · filed 2026-08-13
$583.00K
10-Q · filed 2025-11-05
$784.00K
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$224.00K
10-Q · filed 2026-08-13
$408.00K
10-Q · filed 2026-08-13
$609.00K
derived: sum of 3 quarters · filed 2026-08-13
$831.00K
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31$184.00K
10-Q · filed 2026-05-07
$385.00K
derived: sum of 2 quarters · filed 2026-05-07
$607.00K
derived: sum of 3 quarters · filed 2026-05-07
$770.00K
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$201.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
$423.00K
derived: sum of 2 quarters · filed 2026-03-19
$586.00K
derived: sum of 3 quarters · filed 2026-03-19
$700.00K
10-K · filed 2026-03-19
2024-09-30$222.00K
10-Q · filed 2025-11-05
$474.00K
10-Q · filed 2024-11-14
$385.00K
derived: sum of 2 quarters · filed 2025-11-05
$499.00K
10-Q · filed 2025-11-05
$1.05M
10-Q · filed 2024-11-14
$677.00K
derived: sum of 4 quarters · filed 2025-11-05
2024-06-30$163.00K
10-Q · filed 2025-08-07
$316.00K
10-Q · filed 2024-08-14
$277.00K
10-Q · filed 2025-08-07
$581.00K
10-Q · filed 2024-08-14
$455.00K
derived: sum of 3 quarters · filed 2025-08-07
$459.00K
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31$114.00K
10-Q · filed 2025-05-06
$265.00K
10-Q · filed 2024-05-09
$292.00K
derived: sum of 2 quarters · filed 2025-05-06
$296.00K
derived: sum of 3 quarters · filed 2025-05-06
2023-12-31$178.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28
$182.00K
derived: sum of 2 quarters · filed 2025-03-28
$182.00K
10-K · filed 2025-03-28
$244.00K
10-K · filed 2024-03-29
2023-09-30$4.00K
10-Q · filed 2024-11-14
$4.00K
10-Q · filed 2024-11-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
Equillium, Inc. (EQ)United States$0.109B-11.27
Quantum Cyber N.V. (QUCY)$0.113B
Immuneering Corp (IMRX)United States$0.113B-12.51
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
ProMIS Neurosciences Inc. (PMN)$0.102B
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95